Last reviewed · How we verify

NCT04509557

[177Lu]Ludotadipep Treatment in Patients With Metastatic Castration-resistant Prostate Cancer.

Completed Phase 1 Last updated 20 October 2022
What this trial tests

Phase 1 trial testing [177Lu]Ludotadipep in Metastatic Castration-resistant Prostate Cancer in 30 participants. Completed in 30 June 2022.

Timeline
14 October 2020
Primary endpoint
30 June 2022
30 June 2022

Quick facts

Lead sponsorFutureChem
PhasePhase 1
StatusCompleted
Study typeINTERVENTIONAL
Allocationnon randomized
Designsequential
Maskingnone
Primary purposetreatment
Enrollment30
Start date14 October 2020
Primary completion30 June 2022
Estimated completion30 June 2022
Sites1 location across South Korea

Drugs / interventions tested

Conditions studied

Sponsor

FutureChem — full company profile →

Who can join

20 and older, male only, with Metastatic Castration-resistant Prostate Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study aims to evaluate the stability and efficacy after administration of \[177Lu\]Ludotadipep in patients with metastatic castration resistant prostate cancer (mCRPC), with dose-escalation applied to determine the appropriate dose.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Status of PSMA-targeted radioligand therapy in prostate cancer: current data and future trials.
    Jang A, Kendi AT, Sartor O. · · 2023 · cited 63× · PMID 36895851 · DOI 10.1177/17588359231157632
  2. More Than Meets the Eye: Scientific Rationale behind Molecular Imaging and Therapeutic Targeting of Prostate-Specific Membrane Antigen (PSMA) in Metastatic Prostate Cancer and Beyond.
    Hyväkkä A, Virtanen V, Kemppainen J, Grönroos TJ, et al · · 2021 · cited 22× · PMID 34067046 · DOI 10.3390/cancers13092244
  3. A Single Dose of Novel PSMA-Targeting Radiopharmaceutical Agent [<sup>177</sup>Lu]Ludotadipep for Patients with Metastatic Castration-Resistant Prostate Cancer: Phase I Clinical Trial.
    Shin D, Ha S, O JH, Rhew SA, et al · · 2022 · cited 14× · PMID 36551710 · DOI 10.3390/cancers14246225
  4. Targeting P21-Activated Kinase-1 for Metastatic Prostate Cancer.
    Somanath PR, Chernoff J, Cummings BS, Prasad SM, et al · · 2023 · cited 11× · PMID 37190165 · DOI 10.3390/cancers15082236
  5. Current Status of PSMA-Targeted Radioligand Therapy in the Era of Radiopharmaceutical Therapy Acquiring Marketing Authorization.
    Oh SW, Suh M, Cheon GJ. · · 2022 · cited 9× · PMID 36425273 · DOI 10.1007/s13139-022-00764-4
  6. PSMA theragnostics for metastatic castration resistant prostate cancer.
    Song H, Guja KE, Iagaru A. · · 2022 · cited 8× · PMID 35659674 · DOI 10.1016/j.tranon.2022.101438
  7. Dosimetric Analysis of a Phase I Study of PSMA-Targeting Radiopharmaceutical Therapy With [&lt;sup&gt;177&lt;/sup&gt;Lu]Ludotadipep in Patients With Metastatic Castration-Resistant Prostate Cancer.
    Ha S, O JH, Park C, Boo SH, et al · · 2024 · cited 7× · PMID 38288897 · DOI 10.3348/kjr.2023.0656
  8. A Treatment Paradigm Shift: Targeted Radionuclide Therapies for Metastatic Castrate Resistant Prostate Cancer.
    Parent EE, Kase AM. · · 2022 · cited 6× · PMID 36077820 · DOI 10.3390/cancers14174276

Verify or expand the search:

Other trials of [177Lu]Ludotadipep

Trials testing the same drug.

Other recruiting trials for Metastatic Castration-resistant Prostate Cancer

Currently open trials in the same condition.

Other FutureChem trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04509557.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing